Phenotypic Variation of and Effect of Dietary Protein on Selected Measures of Immunocompetence in the Cotton Rat (Sigmodon Hispidus)

The study of immune function in wild mammalian populations has been limited. The immunocompetence of wild mammals undoubtedly contributes to their survival and thus to the dynamics of the population as a whole. We selected the hispid cotton rat, Sigmodon hispidus, as a model for the development of immunoassays which are applicable to outbred wild populations and for the assessment of the effects of various extrinsic factors (nutrition and captivity) and intrinsic factors (age, gender) on selected measures of immunocompetence. This thesis is comprised of six manuscripts formatted for submission to Journal of Exper1mental Zoology (Chapter I), Journal of Mammalogy (Chapters II and IV), Developmental and Comparative Immunology (Chapter III), and Canadian Journal of Zoology (Chapters V). The manuscripts are complete as written and need no supporting material.Zoolog

Rat-to-Human Transmission of Cowpox Infection

We isolated Cowpox virus (CPXV) from the ulcerative eyelid lesions of a 14-year-old girl, who had cared for a clinically ill wild rat that later died. CPXV isolated from the rat (Rattus norvegicus) showed complete homology with the girl’s virus. Our case is the first proven rat-to-human transmission of cowpox

Formaldehyde-releasers: relationship to formaldehyde contact allergy. Contact allergy to formaldehyde and inventory of formaldehyde-releasers

This is one of series of review articles on formaldehyde and formaldehyde-releasers (others: formaldehyde in cosmetics, in clothes and in metalworking fluids and miscellaneous). Thirty-five chemicals were identified as being formaldehyde-releasers. Although a further seven are listed in the literature as formaldehyde-releasers, data are inadequate to consider them as such beyond doubt. Several (nomenclature) mistakes and outdated information are discussed. Formaldehyde and formaldehyde allergy are reviewed: applications, exposure scenarios, legislation, patch testing problems, frequency of sensitization, relevance of positive patch test reactions, clinical pattern of allergic contact dermatitis from formaldehyde, prognosis, threshold for elicitation of allergic contact dermatitis, analytical tests to determine formaldehyde in products and frequency of exposure to formaldehyde and releasers. The frequency of contact allergy to formaldehyde is consistently higher in the USA (8-9%) than in Europe (2-3%). Patch testing with formaldehyde is problematic; the currently used 1% solution may result in both false-positive and false-negative (up to 40%) reactions. Determining the relevance of patch test reactions is often challenging. What concentration of formaldehyde is safe for sensitive patients remains unknown. Levels of 200-300 p.p.m. free formaldehyde in cosmetic products have been shown to induce dermatitis from short-term use on normal skin

Melanoma incidence and mortality in Scotland 1979–2003

We studied 12 450 cases of invasive melanoma diagnosed in Scotland in 1979–2003, by thickness, pathological type, and body site at ages under 40, 40–59, and 60 years and over. Melanoma incidence trebled in males from 3.57 to 10.93/105 per year, and increased 2.3-fold in females from 5.60 to 12.96/105 per year. The rate of increase fell in each successive 5-year period. The greatest increase was in males aged 60 years and over at diagnosis. Significant incidence increases were seen in melanomas <1 mm in all three age groups, but those >4 mm only increased significantly at ages 60 years and over. All histological types increased significantly at ages 60 years and over, and in this age group the greatest increase was seen on the head and neck. Five-year disease-free survival improved steadily. Survival figures for 1994–1998 ranged from 93.6% for males and 95.8% for females with tumours <1 mm, to 52.4 and 48.3%, respectively, for those with tumours >4 mm. Over the 25 years, melanoma mortality doubled in males from 1.1 to 2.4/105 per year, but was unchanged in females at 1.5/105 per year. Public education on melanoma is required both for primary prevention and earlier diagnosis, particularly for older males

IGFBP3 mRNA expression in benign and malignant breast tumors

INTRODUCTION: Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk. Emerging evidence over the past few years suggests that IGFBP-3 may act directly on mammary epithelial cells. METHODS: To understand the role of IGFBP-3 in breast tumorigenesis, we investigated IGFBP3 mRNA expression levels in benign and malignant breast tumors and their adjacent normal tissues using real-time quantitative PCR. RESULTS: Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues (p < 0.001). IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than in those who had non-proliferative benign tumors. Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue. There were no apparent associations of IGFBP3 expression in cancer tissues with either overall survival or disease-free survival in a cohort of 521 patients with breast cancer. CONCLUSION: Our findings suggest that the expression level of IGFBP3 in breast tissues may be involved in breast tumorigenesis

Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome

INTRODUCTION: Insulin-like growth factor binding protein-3 (IGFBP-3) differentially modulates breast epithelial cell growth through insulin-like growth factor (IGF)-dependent and IGF-independent pathways and is a direct (IGF-independent) growth inhibitor as well as a mitogen that potentiates EGF (epidermal growth factor) and interacts with HER-2. Previously, high IGFBP-3 levels in breast cancers have been determined by enzyme-linked immunosorbent assay and immunoradiometric assay methods. In vitro, IGFBP-3's mechanisms of action may involve cell membrane binding and nuclear translocation. To evaluate tumour-specific IGFBP-3 expression and its subcellular localisation, this study examined immunohistochemical IGFBP-3 expression in a series of invasive ductal breast cancers (IDCs) with synchronous ductal carcinomas in situ (DCIS) in relation to clinicopathological variables and patient outcome. METHODS: Immunohistochemical expression of IGFBP-3 was evaluated with the sheep polyclonal antiserum (developed in house) with staining performed as described previously. RESULTS: IGFBP-3 was evaluable in 101 patients with a variable pattern of cytoplasmic expression (positivity of 1+/2+ score) in 85% of invasive and 90% of DCIS components. Strong (2+) IGFBP-3 expression was evident in 32 IDCs and 40 cases of DCIS. A minority of invasive tumours (15%) and DCIS (10%) lacked IGFBP-3 expression. Nuclear IGFBP-3 expression was not detectable in either invasive cancers or DCIS, with a consistent similarity in IGFBP-3 immunoreactivity in IDCs and DCIS. Positive IGFBP-3 expression showed a possible trend in association with increased proliferation (P = 0.096), oestrogen receptor (ER) negativity (P = 0.06) and HER-2 overexpression (P = 0.065) in invasive tumours and a strong association with ER negativity (P = 0.037) in DCIS. Although IGFBP-3 expression was not an independent prognosticator, IGFBP-3-positive breast cancers may have shorter disease-free and overall survivals, although these did not reach statistical significance. CONCLUSIONS: Increased breast epithelial IGFBP-3 expression is a feature of tumorigenesis with cytoplasmic immunoreactivity in the absence of significant nuclear localisation in IDCs and DCIS. There are trends between high levels of IGFBP-3 and poor prognostic features, suggesting that IGFBP-3 is a potential mitogen. IGFBP-3 is not an independent prognosticator for overall survival or disease-free survival, to reflect its dual effects on breast cancer growth regulated by complex pathways in vivo that may relate to its interactions with other growth factors

The immunology of wild Rodents: Current Status and Future Prospects

Wild animals’ immune responses contribute to their evolutionary fitness. These responses are moulded by selection to be appropriate to the actual antigenic environment in which the animals live, but without imposing an excessive energetic demand which compromises other component of fitness. But, exactly what these responses are, and how they compare with those of laboratory animals, has been little studied. Here, we review the very small number of published studies of immune responses of wild rodents, finding general agreement that their humoral (antibody) responses are highly elevated when compared with those of laboratory animals, and that wild rodents’ cellular immune system reveals extensive antigenic exposure. In contrast, proliferative and cytokine responses of ex vivo-stimulated immune cells of wild rodents are typically depressed compared with those of laboratory animals. Collectively, these responses are appropriate to wild animals’ lives, because the elevated responses reflect the cumulative exposure to infection, while the depressed proliferative and cytokine responses are indicative of effective immune homeostasis that minimizes immunopathology. A more comprehensive understanding of the immune ecology of wild animals requires (i) understanding the antigenic load to which wild animals are exposed, and identification of any key antigens that mould the immune repertoire, (ii) identifying immunoregulatory processes of wild animals and the events that induce them, and (iii) understanding the actual resource state of wild animals, and the immunological consequences that flow from this. Together, by extending studies of wild rodents, particularly addressing these questions (while drawing on our immunological understanding of laboratory animals), we will be better able to understand how rodents’ immune responses contribute to their fitness in the wild

Antigen presentation and systematic immune responses to herpes simplex virus in patients with recrudescent facial herpetic infections

There is evidence that cell mediated immunity is important in the recovery from herpes simplex virus (HSV) infections but antibodies may help prevent spread of the virus to the nervous system. In this study the relationship between lymphoproliferative and antibody responses to HSV was examined during and after recrudescent HSV infection in healthy volunteers with facial HSV infection and control subjects with no history of herpetic infection. All patients had circulating antibodies to HSV and HSV-specific in vitro lymphoproliferation; controls were negative for both tests. The lymphoproliferative response to HSV was shown to fluctuate: during recrudescence it was low, rose to a peak 5-8 weeks later, and declined over several weeks to a positive background level. Lymphoproliferation with concanavalin A (con A) and circulating anti-HSV antibody titres were high throughout and peripheral blood mononuclear cell subsets remained normal. Evidence was obtained that reduced lymphoproliferative responses to HSV during recrudescence were due to HSV-specific suppressor T cell function rather than lack of responsive T cells. This may cause depression of normal cell mediated immune responses to HSV during asymptomatic recurrences, allowing recrudescent lesions to develop. Three patients with severe eczema herpeticum had absent cell mediated immunity to HSV for many months after recovery from the infection despite normal responses to con A, circulating anti-HSV antibody levels and peripheral blood mononuclear cell subsets. Experimental results suggested that impaired cell mediated immunity to HSV, which might have contributed to the severity of their infection, could be due to suppressor function of CD8+ cells. Activation of helper T cells, which is necessary for effective local cell mediated immune responses to epidermal HSV infection, required presentation of HSV antigen on the surface of antigen presenting cells in the context of Major Histocompatibility Complex (MHC) class II antigen. Epidermal cells, particularly Langerhans cells have antigen presenting function for many antigens. The antigen presenting function of epidermal cells for HSV was investigated in patients with recrudescent HSV infections. Epidermal cell suspensions, prepared from suction blister roofs, and glass-adherent peripheral blood mononuclear cells both presented HSV to immune T cells but epidermal cells were more efficient antigen presenting cells than adherent cells on a per cell basis. Antigen presentation was carried out by DP+ DQ+ DR+ CD1a+ epidermal cells, shown to be Langerhans cells by electron microscopy. Preincubation of epidermal or blood adherent cells with monoclonal antibodies to MHC class II DP, DQ or DR antigens blocked lymphoproliferative responses to HSV. Depletion of DP+ cells from adherent cells also depleted DR+ and DQ+ cells and the antigen presenting cell function of adherent cells was concentrated in cells expressing DP, DQ and DR Ag.</p